Compare DAC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | DAWN |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2006 | 2021 |
| Metric | DAC | DAWN |
|---|---|---|
| Price | $132.42 | $21.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $112.50 | $24.43 |
| AVG Volume (30 Days) | 73.0K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | N/A | $55.03 |
| Revenue Next Year | N/A | $28.12 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $82.75 | $5.64 |
| 52 Week High | $135.21 | $21.53 |
| Indicator | DAC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 70.92 | 80.29 |
| Support Level | $91.64 | $10.30 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.52 | 0.03 |
| MACD | 1.25 | -0.28 |
| Stochastic Oscillator | 86.41 | 90.91 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.